Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model

<p>Abstract</p> <p>Background</p> <p>The purpose of this study was to evaluate the biodistribution and toxicity of amphotericin B (AmB) following multiple oral administrations of a novel tropically stable lipid-based formulation (iCo-010).</p> <p>Methods<...

Full description

Bibliographic Details
Main Authors: Owen David, Zhao Jinying, Wasan Ellen K, Lin Molly, Gershkovich Pavel, Sivak Olena, Clement John G, Wasan Kishor M
Format: Article
Language:English
Published: BMC 2011-08-01
Series:Lipids in Health and Disease
Subjects:
Online Access:http://www.lipidworld.com/content/10/1/135
id doaj-871db15d866241399a3bbc778a8afec4
record_format Article
spelling doaj-871db15d866241399a3bbc778a8afec42020-11-25T01:32:41ZengBMCLipids in Health and Disease1476-511X2011-08-0110113510.1186/1476-511X-10-135Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse modelOwen DavidZhao JinyingWasan Ellen KLin MollyGershkovich PavelSivak OlenaClement John GWasan Kishor M<p>Abstract</p> <p>Background</p> <p>The purpose of this study was to evaluate the biodistribution and toxicity of amphotericin B (AmB) following multiple oral administrations of a novel tropically stable lipid-based formulation (iCo-010).</p> <p>Methods</p> <p>BALB/c mice were allocated into six groups: oral iCo-010 twice daily for 5 days in the dose of 20, 10, 5 and 2.5 mg/kg; vehicle control; and intravenous boluses of Fungizone<sup>® </sup>2 mg/kg once daily for 5 days. The animals were sacrificed 12 h following the last administration and blood and tissues were collected.</p> <p>Results</p> <p>The plasma concentrations of AmB were similar to previously reported after administration of iCo-009. Somewhat lower concentrations of AmB were detected in reticulo-endothelial system in the case of iCo-010 when compared with iCo-009. The concentration in kidney was higher with iCo-010 than with iCo-009. The creatinine levels in all oral treatment groups were in a normal range as in the case of iCo-009. Administration of Fungizone<sup>® </sup>resulted in elevated plasma creatinine levels. Histopathology analysis detected no GI, liver or kidney toxicity following multiple dose oral administration of iCo-010. Fungizone<sup>® </sup>treatment induced necrotic changes in hepatic and kidney tissues.</p> <p>Conclusions</p> <p>Given the tropical stability of iCo-010, near identical activity against visceral leishmaniasis and significant concentrations in target organs this formulation has a potential to become a treatment of choice in tropical developing countries.</p> http://www.lipidworld.com/content/10/1/135Lipid-based formulationIntestinal absorptionNephrotoxicityTissue distributionAmphotericin B
collection DOAJ
language English
format Article
sources DOAJ
author Owen David
Zhao Jinying
Wasan Ellen K
Lin Molly
Gershkovich Pavel
Sivak Olena
Clement John G
Wasan Kishor M
spellingShingle Owen David
Zhao Jinying
Wasan Ellen K
Lin Molly
Gershkovich Pavel
Sivak Olena
Clement John G
Wasan Kishor M
Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model
Lipids in Health and Disease
Lipid-based formulation
Intestinal absorption
Nephrotoxicity
Tissue distribution
Amphotericin B
author_facet Owen David
Zhao Jinying
Wasan Ellen K
Lin Molly
Gershkovich Pavel
Sivak Olena
Clement John G
Wasan Kishor M
author_sort Owen David
title Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model
title_short Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model
title_full Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model
title_fullStr Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model
title_full_unstemmed Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model
title_sort tropically stable novel oral lipid formulation of amphotericin b (ico-010): biodistribution and toxicity in a mouse model
publisher BMC
series Lipids in Health and Disease
issn 1476-511X
publishDate 2011-08-01
description <p>Abstract</p> <p>Background</p> <p>The purpose of this study was to evaluate the biodistribution and toxicity of amphotericin B (AmB) following multiple oral administrations of a novel tropically stable lipid-based formulation (iCo-010).</p> <p>Methods</p> <p>BALB/c mice were allocated into six groups: oral iCo-010 twice daily for 5 days in the dose of 20, 10, 5 and 2.5 mg/kg; vehicle control; and intravenous boluses of Fungizone<sup>® </sup>2 mg/kg once daily for 5 days. The animals were sacrificed 12 h following the last administration and blood and tissues were collected.</p> <p>Results</p> <p>The plasma concentrations of AmB were similar to previously reported after administration of iCo-009. Somewhat lower concentrations of AmB were detected in reticulo-endothelial system in the case of iCo-010 when compared with iCo-009. The concentration in kidney was higher with iCo-010 than with iCo-009. The creatinine levels in all oral treatment groups were in a normal range as in the case of iCo-009. Administration of Fungizone<sup>® </sup>resulted in elevated plasma creatinine levels. Histopathology analysis detected no GI, liver or kidney toxicity following multiple dose oral administration of iCo-010. Fungizone<sup>® </sup>treatment induced necrotic changes in hepatic and kidney tissues.</p> <p>Conclusions</p> <p>Given the tropical stability of iCo-010, near identical activity against visceral leishmaniasis and significant concentrations in target organs this formulation has a potential to become a treatment of choice in tropical developing countries.</p>
topic Lipid-based formulation
Intestinal absorption
Nephrotoxicity
Tissue distribution
Amphotericin B
url http://www.lipidworld.com/content/10/1/135
work_keys_str_mv AT owendavid tropicallystablenovelorallipidformulationofamphotericinbico010biodistributionandtoxicityinamousemodel
AT zhaojinying tropicallystablenovelorallipidformulationofamphotericinbico010biodistributionandtoxicityinamousemodel
AT wasanellenk tropicallystablenovelorallipidformulationofamphotericinbico010biodistributionandtoxicityinamousemodel
AT linmolly tropicallystablenovelorallipidformulationofamphotericinbico010biodistributionandtoxicityinamousemodel
AT gershkovichpavel tropicallystablenovelorallipidformulationofamphotericinbico010biodistributionandtoxicityinamousemodel
AT sivakolena tropicallystablenovelorallipidformulationofamphotericinbico010biodistributionandtoxicityinamousemodel
AT clementjohng tropicallystablenovelorallipidformulationofamphotericinbico010biodistributionandtoxicityinamousemodel
AT wasankishorm tropicallystablenovelorallipidformulationofamphotericinbico010biodistributionandtoxicityinamousemodel
_version_ 1725080452187815936